NeOnc Technologies Holdings, Inc. (NTHI) entered into an At‑the‑Market (ATM) equity distribution agreement on April 10, 2026 with BTIG, LLC and A.G.P./Alliance Global Partners that allows the company to sell up to $75 million of common stock on a continuous basis as market conditions permit.
The agreement specifies a 3.0 % commission to the placement agent and allows the company to price shares at the prevailing market level. Proceeds will be used to satisfy withholding tax obligations of roughly $7 million, fund ongoing Phase II and Phase III trials of its intranasal perillyl alcohol platform, and provide general working capital.
NTHI’s financial position underscores the need for this financing. As of the latest filing, the company reported a cash balance of $1.51 million and an accumulated deficit of $112.75 million, a significant increase from the $97.23 million deficit reported earlier in the year. The company also posted a net loss of $62.15 million for 2025, up sharply from $11.9 million in 2024, reflecting the heavy R&D spend required for its clinical pipeline.
The ATM program is intended to support the company’s key drug candidates, NEO100 and NEO212, which are in Phase IIa and Phase I/II trials for glioma and meningioma. Management highlighted the importance of these trials as “important inflection points” in a recent quarterly update, noting that the completion of NEO212’s Phase 1 and full enrollment of the NEO100 Phase 2a study are critical milestones for future regulatory submissions.
Insider activity has reinforced investor confidence: President Amir F. Heshmatpour purchased 10,000 shares on April 10 and 15,000 shares on April 9, a total of 25,000 shares. Analyst coverage remains neutral, reflecting the balance between the company’s high cash burn and the potential upside of its clinical program.
The ATM offering provides NTHI with a flexible, lower‑cost financing option that can be deployed as market conditions allow, thereby extending the company’s runway and reducing the need for additional equity dilution or debt issuance. The ability to raise capital opportunistically is critical for a clinical‑stage biotechnology firm whose survival hinges on timely data releases and regulatory approvals.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.